Phase 3 efficacy and safety trial of proposed liraglutide biosimilar for reduction of glycosylated hemoglobin (HbA1c) in patients with Type 2 diabetes mellitus.
- DOI
- 10.1016/j.diabres.2023.111034
- Published
- 2023-12-05
- Container
- Diabetes Res Clin Pract
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.diabres.2023.111034,
title = {Phase 3 efficacy and safety trial of proposed liraglutide biosimilar for reduction of glycosylated hemoglobin (HbA1c) in patients with Type 2 diabetes mellitus.},
author = {Krishnan K and Raman S and Anand Moses CR and Rajesh RP and Gupta A and Mudaliar V and Vimal J.},
year = {2024},
journal = {Diabetes Res Clin Pract},
doi = {10.1016/j.diabres.2023.111034},
url = {https://doi.org/10.1016/j.diabres.2023.111034}
}RIS
TY - JOUR TI - Phase 3 efficacy and safety trial of proposed liraglutide biosimilar for reduction of glycosylated hemoglobin (HbA1c) in patients with Type 2 diabetes mellitus. AU - Krishnan K AU - Raman S AU - Anand Moses CR AU - Rajesh RP AU - Gupta A AU - Mudaliar V AU - Vimal J. PY - 2024 JO - Diabetes Res Clin Pract DO - 10.1016/j.diabres.2023.111034 UR - https://doi.org/10.1016/j.diabres.2023.111034 ER -
APA
K, K., S, R., CR, A. M., RP, R., A, G., V, M., & J., V. (2024). Phase 3 efficacy and safety trial of proposed liraglutide biosimilar for reduction of glycosylated hemoglobin (HbA1c) in patients with Type 2 diabetes mellitus.. Diabetes Res Clin Pract. https://doi.org/10.1016/j.diabres.2023.111034
Source records
- europe-pmc · retrieved 2026-09-26T20:22:31.963Z